Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: A prospective observational study

Clinical Transplantation

Volumn 26, Issue 3, 2012, Pages 393-402

  Evenepoel, Pieter ^a   Sprangers, Ben ^a   Lerut, Evelyne ^b   Bammens, Bert ^a   Claes, Kathleen ^a   Kuypers, Dirk ^a   Meijers, Björn ^a   Vanrenterghem, Yves ^a  

^a Division of Nephrology   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Hyperparathyroidism cinacalcet; Kidney transplantation; Nephrocalcinosis; Parathyroidectomy; Post transplant mineral metabolism

Indexed keywords

CALCITRIOL; CALCIUM ION; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HORMONE BLOOD LEVEL; HUMAN; HYPERPARATHYROIDISM; INCIDENCE; INTRAOPERATIVE PERIOD; KIDNEY CALCIFICATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT WITHDRAWAL; URINE LEVEL;

CALCIUM; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MINERALS; NAPHTHALENES; NEPHROCALCINOSIS; PARATHYROID HORMONE; PARATHYROIDECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84862252187     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01524.x     Document Type: Article

References (49)

1. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006: 70: 1358.
2. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002: 13: 2762.
3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001: 12: 2131.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004: 15: 2208.
5. Urena P, Jacobson SH, Zitt E et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study. Nephrol Dial Transplant 2009: 24: 2852.
6. Block GA, Martin KJ, De Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004: 350: 1516.
7. Lindberg JS. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int Suppl 2005: 95: S33.
8. Kestenbaum B, Seliger SL, Gillen DL et al. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int 2004: 65: 282.
9. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005: 68: 1793.
10. Setterberg L, Sandberg J, Elinder CG, Nordenstrom J. Bone demineralization after renal transplantation: contribution of secondary hyperparathyroidism manifested by hypercalcaemia. Nephrol Dial Transplant 1996: 11: 1825.
11. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997: 30: 606.
12. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005: 5: 1934.
13. Evenepoel P, Lerut E, Naesens M et al. Localization, etiology and impact of calcium phosphate deposits in renal allografts. Am J Transplant 2009: 9: 2470.
14. Jadoul M, Banos A, Zani VJ, Hercz G. The effects of discontinuing cinacalcet at the time of kidney transplantation. NDT Plus 2010: 3: 37.
15. Torregrosa JV, Bergua C, Martinez de Osaba MJ, Oppenheimer F, Campistol JM. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis. Transplant Proc 2009: 41: 2396.
16. Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant 2007: 22: 1730.
17. Ito N, Fukumoto S, Takeuchi Y et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 2005: 23: 435.
18. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004: 44: 250.
19. Bouillon R, Van Herck E, Jans I, Tan BK, Van Baelen H, De Moor P. Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 1984: 30: 1731.
20. Bouillon R, De Moor P, Baggiolini EG, Uskokovic MR. A radioimmunoassay for 1, 25-dihydroxycholecalciferol. Clin Chem 1980: 26: 562.
21. Bouillon R, Coopmans W, Degroote DE, Radoux D, Eliard PH. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 1990: 36: 271.
22. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006: 70: 345.
23. Bosma RJ, Doorenbos CR, Stegeman CA, Van Der Heide JJ, Navis G. Predictive performance of renal function equations in renal transplant recipients: an analysis of patient factors in bias. Am J Transplant 2005: 5: 2193.
24. Evenepoel P, Van Den BB, Naesens M et al. Calcium metabolism in the early posttransplantation period. Clin J Am Soc Nephrol 2009: 4: 665.
25. Cundy T, Kanis JA, Heynen G, Morris PJ, Oliver DO. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 1983: 52: 67.
26. Ramezani M, Einollahi B, Asl MA et al. Calcium and phosphorus metabolism disturbances after renal transplantation. Transplant Proc 2007: 39: 1033.
27. Stavroulopoulos A, Cassidy MJ, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant recipients. Am J Transplant 2007: 7: 2546.
28. Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998: 13: 436.
29. David DS, Sakai S, Brennan BL et al. Hypercalcemia after renal transplantation. Long-term follow-up data. N Engl J Med 1973: 289: 398.
30. Parfitt AM. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982: 8: 92.
31. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000: 289: 1504.
32. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004: 19: 1281.
33. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009: 24: 982.
34. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007: 22: 577.
35. Sprague SM, Evenepoel P, Curzi MP et al. Simultaneous control of PTH and CaxP is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 2009: 4: 1465.
36. Komaba H, Fukagawa M. Regression of parathyroid hyperplasia by calcimimetics - fact or illusion? Nephrol Dial Transplant 2009: 24: 707.
37. Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007: 22: 1828.
38. Triponez F, Clark OH, Vanrenthergem Y, Evenepoel P. Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg 2008: 248: 18.
39. Viaene L, Evenepoel P, Bammens B, Claes K, Kuypers D, Vanrenterghem Y. Calcium requirements after parathyroidectomy in patients with refractory secondary hyperparathyroidism. Nephron Clin Pract 2008: 110: c80.
40. Ozdemir FN, Afsar B, Akgul A, Usluogullari C, Akcay A, Haberal M. Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients. Transplant Proc 2006: 38: 480.
41. Vervaet BA, Verhulst A, D'Haese PC, De Broe ME. Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol Dial Transplant 2009: 24: 2030.
42. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004: 15: 2857.
43. Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007: 21: 558.
44. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007: 22: 2362.
45. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006: 1: 323.
46. Leca N, Laftavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006: 6: 2391.
47. El Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007: 83: 546.
48. Szwarc I, Argiles A, Garrigue V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006: 82: 675.
49. Bergua C, Torregrosa JV, Cofan F, Oppenheimer F. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc 2007: 39: 2254.